期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

治疗2型糖尿病的新型药物——西他列汀 被引量：8

下载PDF
导出
摘要 目前，二肽基肽酶Ⅳ（DPP-Ⅳ）抑制剂类降糖药成为研究热点，它属于非胰岛素治疗药物，主要涉及2型糖尿病病理过程中的信号传导过程，通过抑制在体内降解外源性肠促胰岛素（GLP）-1的DPP-ⅣV，抑制胰高血糖素的分泌和胰岛β细胞增殖及提高葡萄糖耐受水平，与易增加体重及引起水肿的传统口服降糖药物相比，该类新药疗效明显，能针对2型糖尿病的3种主要缺陷：胰岛素抵抗、β细胞功能障碍（胰岛素的释放减少）以及α细胞功能障碍（未抑制肝葡萄糖的产生）发挥作用。
作者 许菁 王玉丽 徐为人 张士俊
机构地区 天津医科大学基础医学院 天津药物研究院药物创新中心
出处 《中国药物与临床》 CAS 2007年第11期861-863,共3页 Chinese Remedies & Clinics
关键词 2型糖尿病 治疗药物 新型药物 细胞功能障碍 葡萄糖耐受 口服降糖药 二肽基肽酶Ⅳ 非胰岛素
分类号 R977.1 [医药卫生—药品]
  • 相关文献

参考文献15

  • 1Gallwitz B.Therapies for the treatment of type 2 diabetes mellitus based on incretinaction.Minerva Endocrinol,2006,31(2):133-147.
  • 2Ahren B,Landin-olsson M,Jansson PA,et al.Inhibition of dipeptidyl peptidase-4 reduces glycemia,sustains insulin levels,and reduces glucagon levels in type 2 diabetes.J Clin Endocrinol Metab,2004,89(5):2078-2084.
  • 3Mu J,Woods J,Zhou YP,et al.Chronic Inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic {beta}-cell mass and function in a rodent model of type 2 diabetes.Diabetes,2006,55(6):1695-1704.
  • 4Drucker DJ,Nauck MA.The incretin system:glucagons-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.Lancet,2006,368(9548):1696-1705.
  • 5Aschner P,Kipnes MS,Lunceford JK,et al.Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.Diabetes care,2006,29(12):2632-2637.
  • 6Kim D,Wang L,Beconi M,et al.(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:a potent,orally active dipeptidyl peptidase-Ⅳ inhibitor for the treatment of type 2 diabetes.J Med Chem,2005,48(1):141-151.
  • 7Herman GA,Berqman A,Stevens C,et al.Effect of single oral doses of sitagliptin,a dipeptidyl peptidase-4 inhibitor,on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.Clin Endocrinol Metab,2006,91(11):4612-4619.
  • 8Miller S,Stonge EL.Sitagliptin:a dipeptidyl peptidase Ⅳ Inhibitor for the treatment of type 2 diabetes.Ann Pharm,2006,40(7-8):1336-1343.
  • 9Scott R,Wu M,Sanchez M,et al.Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.Int J Clin Pract,2007,61(1):171-180.
  • 10Charbonnel B,Karasik A,Liu J,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.Diabetes Care,2006,29 (12):2638-2643.

同被引文献52

  • 1夏玲红.治疗糖尿病的新药西他列汀[J].中国新药杂志,2007,16(12):979-981. 被引量：26
  • 2Mu J, Woods J, Zhou Y P, et al. Chronic. lnhibiton of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic { beta} -cell mass and function in a rodent model of type2 diabetes[J].Diabetes, 2006, 55 (6):1695-1704.
  • 3Rosenstock J, Brazg R, Andryuk P J. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added lo ongoing pioglitazone therapy in patients with type 2 diabetes: a 24 week, multicenter, randomized, double-blind, placebocontrolled, parallel-group study [J]. Clin Ther, 2006, 28 (10):1556-1568.
  • 4Gallwitz B. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes [J].Drugs Today (Barc), 2007, 43 (10): 681-689.
  • 5Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes[J]. Journal of clinical Pratice, 2006, 60 (11): 1454-1454.
  • 6Herman G, Hanefeld M, Wu M, et al. effect of MK-0431, a dipeptidyl peptidase Ⅳ (DPP Ⅳ) inhibitor on glycaemic control after 12 weeks in patients with type 2 diabetes [J]. Diabetes, 2005, 54 (suppl 1): A134, A541-541.
  • 7Charbonnel B, karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone[J]. Diabetes Care, 2006, 29 (12): 2638 2638.
  • 8Mistry G C, Bergman A J, Luo W L, et al. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects [J].Clin Pharmacol, 2007, 47 (2):159-164.
  • 9Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycemic control and beta-cell function in patients with type 2 diabetes [J]. Diabetes Obes Metab, 2007, 9 (2) : 186-193.
  • 10Wei Zeng, Donald G Musson, Alison L Fisher, et al. Determination of MK 0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry[J].Rapid Commun Mass Spectrom, 2006, 20 (8):1169-1175.

引证文献8

二级引证文献14

中国药物与临床
2007年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部